Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TLR4 | O00206 | 7/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17435235 | 1.00 | LMNA (0.55) | LMNAKMT2ATLR4POLBALDH1A1 | |
| SCHEMBL2342150 | 0.91 | LMNA (0.46) | LMNAKMT2ATLR4POLBALDH1A1 | |
| SCHEMBL15928794 | 0.91 | LMNA (0.46) | LMNAKMT2ATLR4POLBALDH1A1 | |
| SCHEMBL2338508 | 0.87 | LMNA (0.62) | LMNAKMT2APOLBALDH1A1TGM2 | |
| SCHEMBL6329773 | 0.87 | LMNA (0.62) | LMNAKMT2APOLBALDH1A1TGM2 | |
| SCHEMBL6329768 | 0.87 | LMNA (0.62) | LMNAKMT2APOLBALDH1A1TGM2 | |
| SCHEMBL22033962 | 0.87 | TSHR (0.38) | LMNAKMT2ATLR4TYMPTSHR | |
| SCHEMBL22033911 | 0.87 | TSHR (0.38) | LMNAKMT2ATLR4TYMPTSHR | |
| SCHEMBL23778467 | 0.81 | TYMP (0.41) | LMNAKMT2AALDH1A1CYP3A4MAPT | |
| SCHEMBL22033913 | 0.80 | MAPT (0.42) | MAPTTYMPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151400-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | UNIV JOHNS HOPKINS (US) | 2016-06-02 | — | — | US | disclosed |
| US-9067960-B2 | Hybrid SCFA-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-06-30 | — | — | US | disclosed |
| US-8916544-B2 | Hybrid SCFA-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140220630-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| US-20110206734-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220630-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | HCAR2, HSD17B14, FASN | LMNA 1218/4885KMT2A 1073/4885TLR4 704/4885 |
| US-20160151400-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | HCAR2, HSD17B14, FASN | LMNA 1218/4885KMT2A 1073/4885TLR4 704/4885 |
| US-20110206734-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | HCAR2, HSD17B14, FASN | LMNA 1218/4885KMT2A 1073/4885TLR4 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.